Perspective Therapeutics, Inc. 8-K

What Happened

• On April 18, 2026, Perspective Therapeutics, Inc. posted a poster to its website showing certain interim results from its Phase 1/2a clinical trial of [212Pb]VMT-α-NET. The poster is being presented at the American Association for Cancer Research Annual Meeting 2026 (AACR 2026), held April 17–22, 2026 in San Diego.
• The company filed a Current Report on Form 8-K on April 20, 2026 to disclose the posting; a copy of the poster was included as Exhibit 99.1 to the filing.

Key Details

• Therapy: [212Pb]VMT-α-NET (radiopharmaceutical targeting somatostatin receptor subtype 2).
• Indication: Patients with unresectable or metastatic SSTR2-expressing neuroendocrine tumors.
• Poster posted online: April 18, 2026; AACR conference dates: April 17–22, 2026.
• 8-K filing date/signed by CEO Johan (Thijs) Spoor: April 20, 2026.

Why It Matters

• The filing signals a public release of interim clinical data and formal presentation at a major oncology conference, increasing transparency about the program’s clinical progress. For investors, this is a development-stage clinical update that could precede further data releases or regulatory/clinical milestones; monitor future company communications for detailed results and next steps.